A small investor who currently holds 20 shares of Allergan has filed a proposed securities class action lawsuit seeking to stop its purchase by AbbVie, according to reports.
A small investor who currently holds 20 shares of Allergan has filed a proposed securities class action lawsuit seeking to stop its purchase by AbbVie, according to reports.
In June, AbbVie announced a $63 billion transaction agreement to acquire Allergan at a 45% premium to its trading price ($188 a share).
The shareholder, Yuan Lan Swei, bought 40 shares in 2015 and sold half of them the following year, according to FiercePharma. The New Jersey lawsuit says the proxy statement detailing AbbVie’s proposed Allergan buy leaves out important shareholder info, such as cost savings and expenses. It also says any payouts given to AbbVie executives could cloud their judgement about the deal, which was assessed by analysts to be beneficial to Allergan shareholders.
According to the the report, the shareholder sued on behalf of other investors who could join the class and wants a court to delay the shareholder vote until key information is released.
Meanwhile, both senators as well as advocacy groups and unions have asked the Federal Trade Commission (FTC) to block the deal.
According to Reuters, last week the AbbVie-Allergan deal was cited in a letter to the FTC from a small group of Democratic senators. The letter was led by US presidential hopeful Senator Amy Klobuchar, D-Minnestota, and cites ongoing industry consolidation amidst an affordability crisis in prescription drugs for many Americans. Saying the problem affects 1 in 4 in the United States, the letter says, “It is more important than ever that the FTC take appropriate action to protect consumers from acquisitions that may threaten competition in drug markets, raise drug prices, or reduce patient access to essential medications.”
In addition, about a dozen advocacy groups and unions, including Public Citizen and the American Federation of Teachers, want the FTC to block the deal, and to go beyond what it usually considers when it looks at anticompetitive behavior.
Reuters reported that the groups warned that the deal could lead to a broader use of volume-based rebates or other incentives to insurers or pharmacy benefit managers; the use of such payments are one reason drugmakers have said prescription prices are high. The group also criticized Allergan for practices like attempting to transfer patents for its cyclosporine eye drops (Restasis) to a Native American tribe to protect it from patent challenges and delay market entry of less expensive generic versions.
Unions have long complained about the price of AbbVie’s brand-name Humira, which faced competition in Europe from biosimilar adalimumab for the first time in late 2018. While no adalimumab biosimilars are slated for US launches prior to 2023, the Humira maker has sought to mitigate the impact of biosimilars through the sales of novel agents.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.